Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRX-12251
- Development stage
- Discontinued
- Lead developer
- Prexa
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**PRX-12251** is a small molecule triple reuptake inhibitor (TRI) developed by Prexa Pharmaceuticals for central nervous system disorders. It potently blocks the dopamine transporter (DAT), sodium-dependent noradrenaline transporter (NET), and sodium-dependent serotonin transporter (SERT), with the greatest potency against DAT, aiming to enhance monoamine neurotransmitter levels in the brain for potential treatment of conditions like depression or ADHD. The program raised Series B financing in 2013 to support preclinical studies and Phase 1b trials but has since been discontinued.[1][3][5][11]
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on PRX-12251.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRX-12251.